Cargando…
Structural insights into the non-inhibitory mechanism of the anti-EGFR EgB4 nanobody
BACKGROUND: The epidermal growth factor receptor (EGFR) is involved in various developmental processes, and alterations of its extracellular segment are associated with several types of cancers, in particular glioblastoma multiforme (GBM). The EGFR extracellular region is therefore a primary target...
Autores principales: | Zeronian, Matthieu R., Doulkeridou, Sofia, van Bergen en Henegouwen, Paul M. P., Janssen, Bert J. C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8887186/ https://www.ncbi.nlm.nih.gov/pubmed/35232398 http://dx.doi.org/10.1186/s12860-022-00412-x |
Ejemplares similares
-
A Nanobody‐on‐Quantum Dot Displacement Assay for Rapid and Sensitive Quantification of the Epidermal Growth Factor Receptor (EGFR)
por: Su, Ruifang, et al.
Publicado: (2022) -
Homogeneous tumor targeting with a single dose of HER2-targeted albumin-binding domain-fused nanobody-drug conjugates results in long-lasting tumor remission in mice
por: Xenaki, Katerina T, et al.
Publicado: (2021) -
Dual Targeting of Endothelial and Cancer Cells Potentiates In Vitro Nanobody-Targeted Photodynamic Therapy
por: Mashayekhi, Vida, et al.
Publicado: (2020) -
Expansion of a highly sensitive and specific ELISA test for diagnosis of hydatidosis using recombinant EgB8/2 protein
por: Bashiri, Sareh, et al.
Publicado: (2019) -
Resolving bundled microtubules using anti-tubulin nanobodies
por: Mikhaylova, Marina, et al.
Publicado: (2015)